FinBoss.io
CSEN
  • Crypto prices
  • Liquidation War
  • Crypto tools
  • Bitcoin on-chain
  • US macro
  • US stocks
    • Largest US stocks
    • Stock screener
    • Earnings calendar
    • Insider trading
    • Market heatmap
  • Markets
  • Tools
  • Guides
  • FinBot
FinBoss.io
Crypto prices
Liquidation War
Crypto tools
Altcoin Season Index
Big players (on-chain)
Bitcoin halving countdown
Bear market radar
Bitcoin on-chain
Hashrate
Mining difficulty
Mining pools
Mempool and fees
On-chain activity
MVRV and NUPL
SOPR
Holders
Supply in profit
Rainbow Chart
Fair value
Pi Cycle Top
US macro
FedWatch
Interest rates
Treasury yields
Inflation
Liquidity and Bitcoin
Business cycle
US stocks
Largest US stocks
Stock screener
Earnings calendar
Insider trading
Market heatmap
Markets
Stock indices
Commodities
Forex rates
Bear market radar
Famous investors' portfolios
Tools
Dashboards
Investor dashboardTrader dashboardBeginner dashboard
Calculators
Compound interestDCA calculatorDrawdown recovery
Compare
BrokersCrypto exchanges
Přehled sekce Tools →
Guides
FinBot
CSEN
Home
Stocks
Surgery Partners Inc
SG

Surgery Partners Inc

SGRYNASDAQ

Stock · Data from SEC EDGAR 13F · Held by 2 of 87 tracked investors

$23.36
▲ 0.47%
Famous investorshold 2buying 0selling 0
Price (USD)
$23.36
Market cap
$3B
P/E ratio
–
Tracked investors holding
2 of 87
Next earnings
9 Nov 2026

Surgery Partners Inc at a glance

An overview of the financial statements, in plain language. Switch to the advanced view for charts.

FinBoss score
37out of 100
  • Valuation8
  • Growth63
  • Profitability42
  • Quality38
  • Debt25
  • Stability46
In its favour
  • ✓Revenue grew 9.2% a year over 3 years.
What to watch
  • !The company is loss-making: net profit is negative.
  • !Net debt is high: at the current free cash flow it would take 21 years to repay.
  • !The stock is expensive: you pay 139.5 USD for 1 USD of annual earnings.

The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.

Is the stock expensive?

Expensive

The company has no earnings, so the P/E cannot be calculated.

P/E
–
P/S
0.9×
EV/EBITDA
13.4×

Is the company growing?

Growing
22
23
24
25

Revenue over 3 years grew 9.2% a year. Last year 2.7%.

Does it make money?

Loss-making
  • Cost of sales 77

Revenue and net profit (USD B)

Margins (% of revenue)

Free cash flow and capex (USD B)

Cash and debt (USD B)

Earnings per share (EPS, USD)

Latest quarters (USD B)

Earnings results

QuarterReportedEPSAnalyst estimateSurprise
Jun 202610 Aug 20260.07-0.03+333.3%
Mar 20265 May 2026-0.08-0.17+52.9%
Dec 20252 Mar 20260.100.27-63%
Sep 202510 Nov 20250.110.12-8.3%

EPS is earnings per share. The surprise is the difference against the analysts' consensus. Source: Nasdaq, in dollars.

Chart SGRY

Insider purchases

last 90 days, SEC Form 4
Loading insider trades…

Which investors hold this stock

2
HM
Howard Marks
Oaktree Capital Management
0.2%$14,491,478New position
LB
Louis Bacon
Moore Capital Management
0.01%$840,000unchanged

Frequently asked questions

How much is Surgery Partners Inc (SGRY) stock?

Surgery Partners Inc shares trade at $23.36, +0.47% over the last trading day. The price is delayed.

What is the market cap of Surgery Partners Inc?

The market cap of Surgery Partners Inc is about $3B.

Which big investors hold Surgery Partners Inc?

According to the latest 13F filings, 2 of 87 tracked investors hold Surgery Partners Inc, for example Howard Marks, Louis Bacon.

When will Surgery Partners Inc report its next results?

The next earnings report of Surgery Partners Inc is expected on 9 Nov 2026.

Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.

© 2026 FinBoss.io. All rights reserved.

How we make moneyTerms of usePrivacy policyCookie policy

Disclaimer: the information on this site is for general information only and is not investment or financial advice. Investing involves risk, and cryptocurrencies are especially volatile. Past performance does not guarantee future results. Some links are affiliate links and are marked as ads.

  • Research 0.0
  • Operations and selling 8.9
  • Taxes and other 16.6
  • Net profit -2.4
  • Out of 100 USD of revenue, -2.4 USD is left as net profit.

    Is it financially healthy?

    Watch the debt
    Cash
    217M USD
    Debt
    4.1B USD
    Free CF
    184M USD

    It could repay its net debt from free cash flow in 21.0 years.

    Does it pay a dividend?

    No dividend

    The company pays no dividend. It reinvests the money or holds it.

    What do analysts expect?

    Buy
    Average target
    21.20 USD
    Vs price
    −9%

    5 analysts. Their opinion is not a recommendation by FinBoss.io.

    Which big investors hold it?

    2 of 87

    Among the tracked investors, Howard Marks, Louis Bacon hold the stock according to 13F filings.

    Ratios

    P/E
    –
    Forward P/E
    139.5×
    P/B
    1.8×
    P/S
    0.9×
    PEG
    –
    EV/EBITDA
    13.4×
    Gross margin
    22.5%
    Operating margin
    13.7%
    Net margin
    -2.6%
    ROE
    2.3%
    ROA
    3.7%
    Debt / equity
    1.2×
    Current ratio
    1.9×
    Revenue growth
    2.7%
    Earnings growth
    –
    Beta
    1.91
    Dividend
    0.00%
    Payout ratio
    0%